We are well aware that today patients with HER2-positive or triple-negative breast cancer would be treated differently [29,30]; therefore, we performed a separate exploratory analysis for patients with luminal breast cancer where we did not find different results (Supplement Figure S3). This evidence concerns the gene ERBB2 and breast cancer.